Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

NCT00391053 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3851

Enrollment

INDUSTRY

Sponsor class

Conditions

Orthomyxoviridae Infection
Influenza
Myxovirus Infection

Interventions

BIOLOGICAL: High-Dose Inactivated, Split-Virion Influenza Vaccine
BIOLOGICAL: High-Dose Inactivated, Split-Virion Influenza Vaccine
BIOLOGICAL: High-Dose Inactivated, Split-Virion Influenza Vaccine
BIOLOGICAL: Inactivated, Split-Virion Influenza Vaccine

Sponsor

Sanofi Pasteur, a Sanofi Company